Jakafi 15 MG tablet 60S
Ended Awarded Last action
- Contract number
- SPE2DR26FKKP4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,583
Award facts
- Contract value 100% obligated
- $12,582.95 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $12,582.95 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Jakafi 15 mg tablets (60-count). The delivery order, issued on February 4, 2026, with an ultimate completion date of February 5, 2026, is structured as a firm fixed-price contract with no set-aside designation. This award falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) established through the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy designed to support recurring pharmaceutical supply needs across Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group's PPV-G GEN V contract, awarded in November 2025 with a ceiling value of $499.99 million and extending through December 31, 2036, positions the company as a critical regional pharmaceutical supplier for military medical operations. The contract authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for branded and generic prescription drugs, biologics, over-the-counter medications, and medical consumables. DMS Pharmaceutical Group's established performance across numerous prior delivery orders and its comprehensive product portfolio—spanning oncology treatments, biologics, vaccines, and specialty pharmaceuticals—demonstrate the company's capability to fulfill the specialized requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FKKP4?
SPE2DR26FKKP4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on February 4, 2026.
How much is contract SPE2DR26FKKP4 worth?
The government has obligated $12,583 on SPE2DR26FKKP4.
Is contract SPE2DR26FKKP4 an order under another contract?
Yes. SPE2DR26FKKP4 is a delivery order under SPE2DR25D9367, an indefinite delivery contract.
Was contract SPE2DR26FKKP4 competed?
The extent of competition for SPE2DR26FKKP4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award